Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. (Q51394440)

4 April 2018

title

Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. (English)

1 reference

4 April 2018

metabolic dysfunction–associated steatotic liver disease

main subject

1 reference

8

Toshikazu Yoshikawa

1 reference

4 April 2018

author name string

Hyohun Park

1

1 reference

4 April 2018

Toshihide Shima

2

1 reference

4 April 2018

Kanji Yamaguchi

3

1 reference

4 April 2018

Hironori Mitsuyoshi

4

1 reference

4 April 2018

Masahito Minami

5

1 reference

4 April 2018

Kohichiroh Yasui

6

1 reference

4 April 2018

Yoshito Itoh

7

1 reference

4 April 2018

Michiaki Fukui

9

1 reference

4 April 2018

Goji Hasegawa

10

1 reference

4 April 2018

Naoto Nakamura

11

1 reference

4 April 2018

Mitsuhiro Ohta

12

1 reference

4 April 2018

Hiroshi Obayashi

13

1 reference

4 April 2018

Takeshi Okanoue

14

1 reference

4 April 2018

publication date

24 July 2010

1 reference

4 April 2018

Journal of Gastroenterology

published in

1 reference

4 April 2018

volume

46

1 reference

4 April 2018

page(s)

101-107

1 reference

4 April 2018

issue

1

1 reference

4 April 2018

Nonalcoholic fatty liver disease

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

Steatohepatitis: a tale of two "hits"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

Nonalcoholic fatty liver disease and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in high-performance liquid chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

Hepatic production of VLDL1 but not VLDL2 is related to insulin resistance in normoglycaemic middle-aged subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

Overproduction of large VLDL particles is driven by increased liver fat content in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1-/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

Insulin protects liver cells from saturated fatty acid-induced apoptosis via inhibition of c-Jun NH2 terminal kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

The biosynthesis of hepatic cholesterol esters and triglycerides is impaired in mice with a disruption of the gene for stearoyl-CoA desaturase 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

The relation between insulin sensitivity and the fatty-acid composition of skeletal-muscle phospholipids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

Skeletal muscle membrane lipid composition is related to adiposity and insulin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

Troglitazone downregulates delta-6 desaturase gene expression in human skeletal muscle cell cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0291-8

Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions

21 January 2018

1 reference

12 December 2020

Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis

1 reference

12 December 2020

A novel technique for the determination of body fat by computed tomography

1 reference

12 December 2020

Metabolism of VLDL and LDL subclasses

1 reference

12 December 2020

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

1 reference

12 December 2020

Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance

1 reference

12 December 2020

Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study

1 reference

12 December 2020

10.1007/S00535-010-0291-8

Identifiers

DOI

1 reference

4 April 2018

PubMed ID

20658156

1 reference

4 April 2018